/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

LIQUIDIA CORP

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$33.2778 0.0958(9.58%) LQDA at 04 Dec 2025 04:37 PM Biotechnology
Lowest Today 30.59
Highest Today 33.84
Today’s Open 30.9
Prev. Close 30.79
52 Week High 33.84
52 Week Low 10.37
Day’s Range: Low 30.59 High 33.84
52-Week Range: Low 10.37 High 33.84
1 day return -
1 Week return +3.4
1 month return +20.9
3 month return +17.0
6 month return +91.48
1 year return +203.51
3 year return +545.97
5 year return +1066.78
10 year return -

Institutional Holdings

Caligan Partners LP 9.43

BlackRock Inc 5.68

Farallon Capital Management, L.L.C. 4.92

Vanguard Group Inc 4.17

Findell Capital Management LLC 3.48

Opaleye Management Inc 2.87

Goldman Sachs Group Inc 2.81

Vanguard Total Stock Mkt Idx Inv 2.34

State Street Corp 2.13

HHG PLC 1.90

Deerfield Management Co 1.88

iShares Russell 2000 ETF 1.80

Geode Capital Management, LLC 1.63

Whitefort Capital Management, LP. 1.55

Tyro Capital Management LLC 1.44

Jupiter Merian Glb Eq AbsRet I USD Acc 1.42

TANG CAPITAL MANAGEMENT LLC 1.33

CenterBook Partners LP 1.28

Patient Square Capital 1.18

Susquehanna International Group, LLP 1.16

FMR Inc 1.06

Two Sigma Investments LLC 0.87

Shay Capital LLC 0.82

Fidelity Small Cap Index 0.75

Fidelity Small Cap Growth 0.70

iShares Russell 2000 Growth ETF 0.65

Vanguard Institutional Extnd Mkt Idx Tr 0.60

Oberweis Micro-Cap 0.37

Oberweis Micro-Cap Growth 0.37

Vanguard Russell 2000 ETF 0.36

SPDR® S&P Kensho New Economies Comps ETF 0.35

Fidelity Small Cap Growth K6 0.34

Fidelity Extended Market Index 0.30

State St Russell Sm Cap® Indx SL Cl I 0.26

Schwab US Small-Cap ETF™ 0.26

Vanguard Health Care ETF 0.23

SPDR® S&P Pharmaceuticals ETF 0.22

Schwab Small Cap Index 0.19

NT R2000 Index Fund - NL 0.18

iShares Micro-Cap ETF 0.17

Market Status

Strong Buy: 6

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 1

Fundamentals

Market Cap 2678.59 M

PB Ratio 128.7259

PE Ratio 0.0

Enterprise Value 2880.35 M

Total Assets 230.31 M

Volume 2057192

Company Financials

Annual Revenue FY23:18317000 18.3M, FY22:15935000 15.9M, FY21:12853345 12.9M, FY20:739628 0.7M, FY19:8072120 8.1M

Annual Profit FY23:15728000 15.7M, FY22:13076000 13.1M, FY21:9830434 9.8M, FY20:501916 0.5M, FY19:7264928 7.3M

Annual Net worth FY23:-57585000 -57.6M, FY22:-38365000 -38.4M, FY21:-29781809 -29.8M, FY20:-57491188 -57.5M, FY19:-46389335 -46.4M

Quarterly Revenue Q3/2025:54342000 54.3M, Q2/2025:8837000 8.8M, Q1/2025:3120000 3.1M, Q3/2024:4448000 4.4M, Q2/2024:3659000 3.7M

Quarterly Profit Q3/2025:51169000 51.2M, Q2/2025:7545000 7.5M, Q1/2025:1603000 1.6M, Q3/2024:2883000 2.9M, Q2/2024:2166000 2.2M

Quarterly Net worth Q3/2025:-3533000 -3.5M, Q2/2025:-41579000 -41.6M, Q1/2025:-38367000 -38.4M, Q3/2024:-23155000 -23.2M, Q2/2024:-27942000 -27.9M

Fund house & investment objective

Company Information Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Organisation Biotechnology

Employees 170

Industry Biotechnology

CEO Dr. Roger A. Jeffs Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow